Cite
HARVARD Citation
Naing, A. et al. (n.d.). 174P First-in-human study of NGM707, an ILT2/ILT4 dual antagonist antibody in advanced or metastatic solid tumors: Preliminary monotherapy dose escalation data. Immuno-oncology technology. p. . [Online].